THIRD QUARTER 2023/24 (NOV - JAN)
- Net sales amounts to 30.1 (18.7) MSEK, which is an increase of 61% compared with the corresponding period last year. The growth in the US market is 43% compared with the corresponding period last year.
- Operating profit amounts to 0.3 (-13.8) MSEK (EBIT 1.1%). The operating profit amounted to 6.1 MSEK (EBIT 20.2%) excluding currency effects of -5.7 MSEK, most of which are unrealized internal accounts receivables.
- Profit/loss after tax amounts to 0.8 (-13.6) MSEK, which resulted in profit per share of
SEK 0.05 (-0.74). - Cash flow from operating activities amounts to 2.0 MSEK (-14.1), change in working capital was -2.9 MSEK (8.2) and investing activities -4.0 (-1.2). Total cash flow for the period was -5.0 (-7.1) MSEK. Liquid assets as of 2024-01-31 amount to 28.4 (46.3) MSEK, not including 29.2 MSEK in accounts receivables.
Significant events in the third quarter
- The
US Department of Defense decided to fully fund a clinical study of OPRA™ Implant System on up to 30 patients with transtibial (below-knee) amputations. The study will be performed by theWalter Reed National Military Medical Center .Integrum will supply OPRA™ Implant Systems on commercial terms. - The company held a pre-submission meeting with the
US Food and Drug Administration (FDA). Based on the conclusions from the meeting,Integrum plans to submit a Pre-Market Approval (PMA) application forIntegrum's OPRA™ Implant System in transhumeral amputations based on existing clinical data. Integrum received its final MDR certification. The company's OPRATM Implant System product portfolio has thereby been granted MDR certification and may be freely distributed within the EU for treatment in individuals living with disabilities because of limb loss.- The company established a Center of Excellence at the
Center for Complex Endoprosthetics , Osseointegration and Bionics inKyiv , with the intention to spearhead orthopedic treatment using OPRA™ Implant System in individuals who have suffered limb loss.
- 1 MAY - 31 JANUARY 2022/23 (9 MONTHS)
-
Net sales amounts to 78.1 (56.1) MSEK, which is an increase of 39% compared with the corresponding
period last year. The growth in the US market is 29% compared with the corresponding period last year - Operating profit amounts to 3.9 (-12.5) MSEK (EBIT 5.0%). The operating profit amounted to 2.5 MSEK (EBIT 3.2%), excluding currency effects of 1.4 MSEK, most of which are unrealized internal accounts receivables.
-
Profit/loss after tax amounts to 1.9 (-10.1) MSEK, which resulted in earnings per share of SEK
0.1 (-0.55). - Cash flow from operating activities amounts to 2.6 (-17.1) MSEK. Total cash flow was -13.6 (-29.0) MSEK.
-
During the year, The
Centers for Medicare and Medicaid Services (CMS) granted the osseointegrated external prosthetic connection device Axor II™ a new reimbursement code. The new code is connected to a set reimbursement that will help to drive growth in the US.
CEO's statement
The third quarter has been characterized by record sales figures, mainly driven by our continued expansion in the US and a recent accelerating growth in emerging markets.
Yet another quarter with record sales and profit
Revenues amounted to 30.1 MSEK in the third quarter, corresponding to an increase of 61.2 percent compared to the same period last year. Excluding direct currency effects, operating profit amounted to 6.1 MSEK leading to an EBIT margin of 20.2%.
Enhanced collaborations in the US
In the US, which is our prioritized market, we have worked to deepen existing collaborations with hospitals offering treatment with our innovative products. The work is based on
In November, we announced our plans to apply for pre-market approval (PMA) for the use of the OPRA™ Implant System in above-elbow treatment. Following a successful meeting with the FDA, we are working with high focus to compile the necessary regulatory documentation needed for a formal application.
Expansion into new markets
In December, we announced the establishment of a clinical center of excellence in
The need for
During my last visit in
In
A skilful organization to achieve high growth
We have, time and again, shown the overturning potential in our innovative bone-anchored solutions - based both on a large body of scientific and clinical evidence, as well as important public recognition. As the organization has grown with skilled experts in key positions, we now see an important shift in our regulatory and commercial activities laying the foundation for meaningful growth.
Mölndal,
Rickard Brånemark
Chief Executive Officer
This disclosure contains information that
The interim report can be found here:
https://integrum.se/investor-relations/financial-reports-calendar/
For more information please contact:
Rickard Brånemark, CEO. Phone: +46 70 846 10 61, E-mail: rickard.branemark@integrum.se
Jörgen Svanström, CFO. Phone: +46 70 734 96 60, E-mail: jorgen.svanstrom@integrum.se
Certified Adviser:
The Company's Certified Adviser is
https://news.cision.com/integrum-ab/r/a-new-record-revenue-quarter-with-61--growth,c3937950
https://mb.cision.com/Main/17531/3937950/2637257.pdf
https://mb.cision.com/Public/17531/3937950/81ab2011ab9b83c3.pdf
(c) 2024 Cision. All rights reserved., source